During the past decade, McLaren Health Care Corporation conducted 5 clinical trials. In the 10-year time frame, 5 clinical trials started and 2 clinical trials were completed, i.e. on average, 40% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 2 clinical trials were completed. i.e. 200% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "McLaren Health Care Corporation" are "Heart Failure" (2 trials), "Anemia" (1 trials), "Bleeding Disorder" (1 trials), "Bradycardia" (1 trials) and "Cardiac Arrhythmia" (1 trials). Many other conditions were trialed in "McLaren Health Care Corporation" in a lesser frequency.

Most popular intervention types in "McLaren Health Care Corporation" are "Device" (6 trials) and "Drug" (1 trials). Other intervention types were less common.

The name of intervention was led by "AMPLATZER™ PFO Occluder" (1 trials), "CardioMEMS™ HF System" (1 trials), "DAPT (aspirin and/or P2Y12 receptor inhibitor)" (1 trials), "MPP" (1 trials) and "Pacemaker, ICD, or CRT device" (1 trials). Other intervention names were less common.

The vast majority of trials in "McLaren Health Care Corporation" are 6 trials for "All" genders.

Currently, there are NaN active trials in "McLaren Health Care Corporation". undefined are not yet recruiting, 1 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in McLaren Health Care Corporation, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in McLaren Health Care Corporation, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 5 trials that are defined as “Not Applicable".